Danaher Moves Toward Masimo Acquisition to Bolster Medical Technology Portfolio

The Quick Take

• Danaher (DHR) is reportedly moving toward an acquisition of Masimo (MASI), a patient monitoring leader.
• Masimo specializes in noninvasive monitoring technology and recently acquired Sound United (Bowers & Wilkins).
• A Danaher-Masimo deal would create a formidable medical device and diagnostics platform.

Danaher's move toward acquiring Masimo would mark a significant transaction for a company that has built its reputation on high-quality bolt-on acquisitions in the life sciences and diagnostics sector. Masimo is a technology leader in noninvasive patient monitoring—particularly its pulse oximetry and patient sensors—and holds a dominant position in hospital vital signs monitoring that complements Danaher's existing diagnostics and analytical instruments portfolio. Masimo's stock has been depressed since its controversial acquisition of Sound United, the consumer audio group that owns Bowers & Wilkins and Denon, which many investors viewed as a strategic distraction from Masimo's core medical technology business.

The Danaher acquisition thesis benefits from a potential reversal of the Sound United diversification premium: Danaher would likely divest the consumer audio assets quickly, focusing purely on Masimo's medical monitoring technology and thereby unlocking the latent value that Masimo's management had obscured through the Sound United transaction. For Masimo shareholders who have been frustrated with the stock's underperformance relative to medtech peers, a Danaher acquisition would represent a significant premium exit. The deal would also face limited antitrust scrutiny—Danaher and Masimo have minimal business overlap—which simplifies the regulatory path compared to horizontal mergers in the same product category.

Watch formal announcement of acquisition terms from Danaher, including the proposed acquisition price relative to Masimo's current market capitalization, as the key near-term catalyst. The macro variable is Danaher's current balance sheet capacity and leverage ratio: Danaher has been selective about M&A timing relative to its debt levels following prior large acquisitions, and a Masimo deal's financing structure will signal management's confidence in generating near-term cash flow to service any incremental leverage. Masimo's CEO Joe Kiani's willingness to negotiate—given his history of resisting takeover approaches—will be the biggest deal uncertainty.

Synthesized from 1 source.